Bone marrow microenvironment and the identification of new targets for myeloma therapy

Leukemia

Volumn 23, Issue 1, 2009, Pages 10-24

  Podar, K ^a   Chauhan, D ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CHIR 258; DEXAMETHASONE; EPOTHILONE D; EVEROLIMUS; FLAVOPIRIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PANOBINOSTAT; PERIFOSINE; PI 88; PROTEIN FARNESYLTRANSFERASE INHIBITOR; ROMIDEPSIN; SEMAXANIB; SGN 40; SORAFENIB; TELOMESTATIN; TEMSIROLIMUS; TIPIFARNIB; UNINDEXED DRUG; VANDETANIB; VORINOSTAT;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW DISEASE; CANCER CELL DESTRUCTION; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVITY; CELL ADHESION; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE TARGETING; HEMOSTASIS; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MONOTHERAPY; MULTIGENE FAMILY; MULTIPLE MYELOMA; NATURAL KILLER CELL; OSTEOBLAST; OSTEOCLAST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TARGET CELL;

EID: 58249101211     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.259     Document Type: Review

References (175)

1. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417-1424.
2. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99: 1745-1757.
3. Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: So what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006; 47: 2289-2300.
4. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313-325.
5. Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003; 22: 7396-7402.
6. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585-598.
7. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329-1337, e-pub ahead of print.
8. Sekimoto E, Ozaki S, Ohshima T, Shibata H, Hashimoto T, Abe M et al A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res 2007; 67: 1184-1192.
9. Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M et al. Targeting beta2-microglobulin for induction of tumor apoptosis n human hematological malignancies. Cancer Cell 2006; 10: 295-307.
10. Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 1995; 32: 4-19.
11. Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol 1999; 36 (1 Suppl 3): 14-20.
12. Podar K, Hideshima T, Chauhan D, Anderson KC. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin Ther Targets 2005; 9: 359-381.
13. Beaupre DM, Cepero E, Obeng EA, Boise LH, Lichtenheld MG. R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. Mol Cancer Ther 2004; 3: 179-186.
14. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004; 103: 3271-3277.
15. David E, Schafer-Hales K, Marcus AI, Kaufman JL, Lonial S. Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation. Blood 2007; ASH Annual Meeting Abstracts (110, abstract #1520).
16. Armand JP, Burnett AK, Drach J, Harousseau JL, Lowenberg B, San Miguel J. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. Oncologist 2007; 12: 281-290.
17. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF et al. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007; 110: 1656-1663.
18. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D et al. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol 2007; 139 55-63.
19. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkyl-phospholipid, inhibits Akt and induces in vitro and In vivo cytotoxicity in human multiple myeloma (MM) cells. Blood 2005; 106 (11 (abstract #250)): 128.
20. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C et al Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007; 138: 783-791.
21. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719.
22. David E, Sinha R, Kaufman JL, Lonial S. Perifosine induces DR4/DR5 expression leading to apoptosis that can be enhanced with exogenous TRAIL, and blocked with strategies directed at DR4/DR5 inhibition. Blood 2006; 108, abstract #3446 (ASH Annual Meeting Abstracts).
23. De P, Peng Q, Dey N, McDermitt B, Peng X, Garlich J et al. A vascular targeted pan PI-3 kinase inhibitor, SF1126 with activity against multiple myeloma in vivo. Blood 2006, (108 abstract #244).
24. McMillin DW, Negri J, Delmore J, Hayden P, Mitsiades N, Richardson PG et al. Anti-myeloma activity of selective PI-3K/PDK/mTOR inhibitor BEZ235. Blood 2007; 110, abstract #1185(ASH annual meeting abstracts).
25. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103 3175-3184.
26. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
27. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloyl-methane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-3871.
28. Amit-Vazina M, Shishodia S, Harris D, Van Q, Wang M, Weber D et al Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer 2005; 93: 70-80.
29. Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro fide-cane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005; 105: 4470-4476.
30. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 2000; 109: 823-828.
31. Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J et al Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res 2006; 66: 9714-9721.
32. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-326.
33. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712-3721.
34. Gilmore TD. Introduction to NF-kappaB: Players, pathways, perspectives. Oncogene 2006; 25: 6680-6684.
35. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115-130.
36. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
37. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104-1112.
38. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2006; 66: 6675-6682.
39. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 2006; 25: 6887-6899.
40. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639-16647.
41. Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N et al MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006; 12: 5887-5894.
42. Sanda T, Iida S, Ogura H, Asamitsu K, Murata T, Bacon KB et al. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res 2005; 11: 1974-1982.
43. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004; 101: 6122-6127.
44. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007; 21 2527-2536.
45. Kobune M, Chiba H, Kato J, Kato K, Nakamura K, Kawano Y et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther 2007; 6: 1774-1784.
46. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349 2483-2494.
47. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516-7521.
48. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F et al Small-molecule antagonists of the oncogenic Tcf/betacatenin protein complex. Cancer Cell 2004; 5: 91-102.
49. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004; 104: 607-618.
50. Urashima M, Chauhan D, Hatziyanni M, Ogata A, Hollenbaugh D, Aruffo A et al. CD40 ligand triggers interleukin-6 mediated B cell differentiation. Leuk Res 1996; 20: 507-515.
51. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications. Cancer Res 2004; 64: 2846-2852.
52. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005; 65: 5898-5906.
53. Radtke F, Wilson A, Ernst B, MacDonald HR. The role of Notch signaling during hematopoietic lineage commitment. Immunol Rev 2002; 187 65-74.
54. Radtke F, Raj K. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer 2003; 3: 756-767.
55. Cheng P, Nefedova Y, Miele L, Osborne BA, Gabrilovich D. Notch signaling is necessary but not sufficient for differentiation of dendritic cells. Blood 2003; 102: 3980-3988.
56. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004; 103: 3503-3510.
57. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004; 104: 3697-3704.
58. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511-3515.
59. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005; 106: 3898-3906.
60. Zdzisinska B, Walter-Croneck A, Kandefer-Szerszen M. Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients. Leuk Res 2008; 32: 1763-1769.
61. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
62. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 4048-4053.
63. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I et al Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68: 190-197.
64. Scadden DT. The stem-cell niche as an entity of action. Nature 2006; 441: 1075-1079.
65. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev 2006; 6: 93-106.
66. Yin T, Li L. The stem cell niches in bone. J Clin Invest 2006; 116: 1195-1201.
67. Mariani S, Coscia M, Even J, Peola S, Foglietta M, Boccadoro M et al Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br J Haematol 2001; 113: 1051-1059.
68. Massaia M, Bianchi A, Attisano C, Peola S, Redoglia V, Dianzani U et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 1991; 78: 1770-1780.
69. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
70. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
71. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M et al Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005; 201: 1503-1517.
72. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003; 197: 1667-1676.
73. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B et al Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 2002; 100: 230-237.
74. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992-2998.
75. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
76. Xie J, Wang Y, Freeman III ME, Barlogie B, Yi Q. Beta 2-microglobulin as a negative regulator of the immune system: High concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003; 101: 4005-4012.
77. Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006; 203: 1859-1865.
78. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: Therapeutic implications. Blood 2007; 109: 4839-4845.
79. Kukreja A, Hutchinson A, Mazumder A, Vesole D, Angitapalli R, Jagannath S et al. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: Therapeutic implications. Br J Haematol 2007; 136: 106-110.
80. Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB et al Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol 2007; 178: 7730-7737.
81. Heissig B, Ohki Y, Sato Y, Rafii S, Werb Z, Hattori K. A role for niches in hematopoietic cell development. Hematology 2005; 10: 247-253.
82. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: Home of HSC differentiation and mobilization. Physiology (Bethesda) 2005; 20: 349-356.
83. Podar K, Anderson KC. The pathophysiological role of VEGF in hematological malignancies: Therapeutic implications. Blood 2005; 105: 1383-1395.
84. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286-3294.
85. de Bont ES, Guikema JE, Scherpen F, Meeuwsen T, Kamps WA, Vellenga E et al. Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. Cancer Res 2001; 61: 7654-7659.
86. Scavelli C, Nico B, Cirulli T, Ria R, Di Pietro G, Mangieri D et al Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008; 27: 663-674.
87. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006; 25: 4257-4266.
88. Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C et al Angiogenesis in multiple myeloma. Eur J Cancer 2006; 42: 1581-1590.
89. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286.
90. Podar K, Anderson KC. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle 2007; 6: 538-542.
91. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992-3996.
92. Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. Best pract res 2007; 20: 613-624.
93. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110: 1098-1104.
94. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008; 112 196-207.
95. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160-3165.
96. Berenson JR. Bone disease in myeloma. Curr Treat Options Oncol 2001; 2: 271-283.
97. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003; 97 (3 Suppl): 887-892.
98. Feng R, Oton A, Mapara MY, Anderson G, Belani C, Lentzsch S. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007; 139: 385-397.
99. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaisse JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005; 65 9943-9952.
100. Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S et al MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007; 110: 3744-3752.
101. Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY et al. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/ activity and multiple myeloma cell growth. Blood 2007; 109: 2130-2138.
102. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006; 107: 3098-3105.
103. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025-2034.
104. Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006; 77 233-238.
105. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079-1088.
106. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, Crinquette A et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21: 158-163.
107. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118: 491-504.
108. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338.
109. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
110. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
111. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006; 367 825-831.
112. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007; 370: 1209-1218.
113. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 2006; 6: 1165-1173.
114. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
115. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22 3269-3276.
116. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
117. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
118. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. Blood 2007; 110 (11; abstract 74): 121.
119. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore Sr DF, Whittenberger BF et al. Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232. Blood 2007; 110 (11; abstract 77): 121.
120. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007; 25: 4459-4465.
121. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
122. San Miguel JF, Schlag R, Khuageva N, Shpilberg O, Dimopoulos M, Kropff M et al. MY-3002: A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma. Blood 2007; 110 (11; abstract 73): 121.
123. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100: 9946-9951.
124. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006; 57: 33-47.
125. Podar K, Anderson KC. Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett 2006; 233: 10-15.
126. Harousseau JL, Attal M, Coiteux V, Stoppa A, Hulin C, Benboubker L et al. Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study. J Clin Oncol 2005, ASCO Annual Meeting Proceedings. 2005;23(16S; Part I of II, (1 June Supplement)):2005: 6653.
127. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005; 48: 3684-3687.
128. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-419.
129. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383-6391.
130. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008; 111: 1654-1664.
131. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062.
132. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
133. Badros A, Philip S, Niesvizky R, Goloubeva O, Harris C, Zweibel J et al. Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts). Blood 2007; 110 (11; abstract 1168): 354a.
134. Weber DM, Jagannath S, Mazumder A, Sobecks R, Schiller GJ, Gavino M et al. Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Combination with Bortezomib in Patients with Advanced Multiple Myeloma. Blood 2007; 110: 355a, abstract 1172.
135. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
136. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319-4327.
137. Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F et al alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 2001; 29: 993-1003.
138. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85.
139. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863-872.
140. Wen XY, Stewart AK, Sooknanan RR, Henderson G, Hawley TS, Reimold AM et al. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol 1999; 15: 173-178.
141. Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K et al Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood 2003; 101: 3606-3614.
142. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese EM et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001; 412: 300-307.
143. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 2003; 4: 321-329.
144. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007; 11: 349-360.
145. Ernst M, Gearing DP, Dunn AR. Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. Embo J 1994; 13: 1574-1584.
146. Schaeffer M, Schneiderbauer M, Weidler S, Tavares R, Warmuth M, de Vos G et al. Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases. Mol Cell Biol 2001; 21: 8068-8081.
147. Podar K, Mostoslavsky G, Sattler M, Tai YT, Hayashi T, Catley LP et al. Critical role for Hck-mediated phosphorylation of Gab1 and Gab2 docking proteins in IL-6- induced proliferation and survival of MM cells. J Biol Chem 2004; 279: 21658-21665.
148. Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004; 3: 1259-1262.
149. Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 2003; 8: 337-343.
150. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007; 109: 1220-1227.
151. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
152. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
153. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002; 62: 5019-5026.
154. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006; 34: 1289-1295.
155. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM et al Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708-2717.
156. Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006; 91: 605-612.
157. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2: 581-587.
158. Pelus LM. Peripheral blood stem cell mobilization: New regimens, new cells, where do we stand. Curr Opin Hematol 2008; 15: 285-292.
159. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-1102.
160. DiPersio J, Stadtmauer EA, Nademanee AP, Stiff P, Micallef I, Angell J et al. In vivo mobilization of multiple myeloma cells out of the bone marrow using the CXCR4 inhibitor AMD3100 and bortezomib: implications for sensitization of myeloma cells to apoptosis. Blood 2007; 110: Abstract #445.
161. Podar K, Hideshima T, Tai YT, Richardson PG, Chauhan D, Anderson KC. Emerging therapies for multiple myeloma. Am J Cancer 2006; 5 141-153.
162. Tai YT, Catley L, Li XF, Coffey R, Breitkreutz I, Bae J et al. Immunomodulatory drug Lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. Cancer Res 2005; 65(24) 11712-11720.
163. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001; 20 4519-4527.
164. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood 2004; 103: 689-694.
165. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103 3148-3157.
166. Moreaux J, Hose D, Jourdan M, Reme T, Hundemer M, Moos M et al. TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 2007; 92: 803-811.
167. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021-1030.
168. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2007; 16: 1474-1478.
169. Abroun S, Ishikawa H, Tsuyama N, Liu S, Li FJ, Otsuyama K et al. Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor alpha myeloma cells. Blood 2004; 103: 2291-2298.
170. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230.
171. Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007; 16: 1693-1707.
172. Sharkey J, Khong T, Spencer A. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood 2007; 109 1712-1719.
173. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT et al Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCI). Blood 2007; 109: 1669-1677.
174. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007; 109: 4964-4972.
175. Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG. From the bench to the bedside: Emerging new treatments in multiple myeloma. Best pract res 2007; 20: 797-816.